6KZN
 
 | |
6KXI
 | |
6LBL
 | |
7VTH
 | | The crystal structure of SARS-CoV-2 3CL protease in complex with compound 1 | | 分子名称: | 2-[4-[[4-[bis(fluoranyl)methoxy]-2-methyl-phenyl]amino]-2,6-bis(oxidanylidene)-3-[[3,4,5-tris(fluoranyl)phenyl]methyl]-1,3,5-triazin-1-yl]-N-methyl-ethanamide, 3C-like proteinase | | 著者 | Yamamoto, S, Tachibana, Y. | | 登録日 | 2021-10-29 | | 公開日 | 2022-04-06 | | 最終更新日 | 2023-11-29 | | 実験手法 | X-RAY DIFFRACTION (2 Å) | | 主引用文献 | Discovery of S-217622, a Noncovalent Oral SARS-CoV-2 3CL Protease Inhibitor Clinical Candidate for Treating COVID-19.
J.Med.Chem., 65, 2022
|
|
7VU6
 | | The crystal structure of SARS-CoV-2 3CL protease in complex with compound 3 | | 分子名称: | 3C-like proteinase, 6-[(6-chloranyl-2-methyl-indazol-5-yl)amino]-3-[(1-methyl-1,2,4-triazol-3-yl)methyl]-1-[[2,4,5-tris(fluoranyl)phenyl]methyl]-1,3,5-triazine-2,4-dione | | 著者 | Yamamoto, S, Yamane, J, Tachibana, Y. | | 登録日 | 2021-11-01 | | 公開日 | 2022-04-06 | | 最終更新日 | 2023-11-29 | | 実験手法 | X-RAY DIFFRACTION (1.8 Å) | | 主引用文献 | Discovery of S-217622, a Noncovalent Oral SARS-CoV-2 3CL Protease Inhibitor Clinical Candidate for Treating COVID-19.
J.Med.Chem., 65, 2022
|
|
3EBX
 | | REFINEMENT AT 1.4 ANGSTROMS RESOLUTION OF A MODEL OF ERABUTOXIN B. TREATMENT OF ORDERED SOLVENT AND DISCRETE DISORDER | | 分子名称: | ERABUTOXIN B, SULFATE ION | | 著者 | Smith, J.L, Corfield, P.W.R, Hendrickson, W.A, Low, B.W. | | 登録日 | 1988-01-15 | | 公開日 | 1988-04-16 | | 最終更新日 | 2017-11-29 | | 実験手法 | X-RAY DIFFRACTION (1.4 Å) | | 主引用文献 | Refinement at 1.4 A resolution of a model of erabutoxin b: treatment of ordered solvent and discrete disorder.
Acta Crystallogr.,Sect.A, 44, 1988
|
|
8A0B
 | | Inhibitor binding to HDAC2 | | 分子名称: | 1,2-ETHANEDIOL, 1,3-dihydroisoindol-2-yl-[(2R,4S)-4-phenylpyrrolidin-1-ium-2-yl]methanone, 2-[N-CYCLOHEXYLAMINO]ETHANE SULFONIC ACID, ... | | 著者 | Cleasby, A, Tisi, D. | | 登録日 | 2022-05-27 | | 公開日 | 2022-09-21 | | 最終更新日 | 2022-11-02 | | 実験手法 | X-RAY DIFFRACTION (1.746 Å) | | 主引用文献 | Fragment-Based Discovery of a Novel, Brain Penetrant, Orally Active HDAC2 Inhibitor.
Acs Med.Chem.Lett., 13, 2022
|
|
7ZZS
 | | HDAC2 complexed with an inhibitory ligand | | 分子名称: | (5~{S})-5-(4-chlorophenyl)pyrrolidin-2-one, 1,2-ETHANEDIOL, 2-(cyclohexylazaniumyl)ethanesulfonate, ... | | 著者 | Cleasby, A, Tisi, D. | | 登録日 | 2022-05-26 | | 公開日 | 2022-09-21 | | 最終更新日 | 2022-11-02 | | 実験手法 | X-RAY DIFFRACTION (1.88 Å) | | 主引用文献 | Fragment-Based Discovery of a Novel, Brain Penetrant, Orally Active HDAC2 Inhibitor.
Acs Med.Chem.Lett., 13, 2022
|
|
7ZZP
 | | Structure of HDAC2 complexed with an inhibitory ligand | | 分子名称: | (2S)-2-HYDROXYPROPANOIC ACID, 1,2-ETHANEDIOL, 2-[N-CYCLOHEXYLAMINO]ETHANE SULFONIC ACID, ... | | 著者 | Cleasby, A, Tisi, D. | | 登録日 | 2022-05-25 | | 公開日 | 2022-09-21 | | 最終更新日 | 2023-11-15 | | 実験手法 | X-RAY DIFFRACTION (1.52 Å) | | 主引用文献 | Fragment-Based Discovery of a Novel, Brain Penetrant, Orally Active HDAC2 Inhibitor.
Acs Med.Chem.Lett., 13, 2022
|
|
7ZZR
 | | HDAC2 in complex with inhibitory ligand | | 分子名称: | 1,2-ETHANEDIOL, 2-[N-CYCLOHEXYLAMINO]ETHANE SULFONIC ACID, CALCIUM ION, ... | | 著者 | Cleasby, A, Tisi, D. | | 登録日 | 2022-05-26 | | 公開日 | 2022-09-21 | | 最終更新日 | 2022-11-02 | | 実験手法 | X-RAY DIFFRACTION (2.168 Å) | | 主引用文献 | Fragment-Based Discovery of a Novel, Brain Penetrant, Orally Active HDAC2 Inhibitor.
Acs Med.Chem.Lett., 13, 2022
|
|
7ZZO
 | | HDAC2 in complex with an inhibitor | | 分子名称: | 2-(cyclohexylazaniumyl)ethanesulfonate, CALCIUM ION, DI(HYDROXYETHYL)ETHER, ... | | 著者 | Cleasby, A, Tisi, D. | | 登録日 | 2022-05-25 | | 公開日 | 2022-09-21 | | 最終更新日 | 2022-11-02 | | 実験手法 | X-RAY DIFFRACTION (2 Å) | | 主引用文献 | Fragment-Based Discovery of a Novel, Brain Penetrant, Orally Active HDAC2 Inhibitor.
Acs Med.Chem.Lett., 13, 2022
|
|
7ZZT
 | | Ligand binding to HDAC2 | | 分子名称: | 1,2-ETHANEDIOL, 2-[N-CYCLOHEXYLAMINO]ETHANE SULFONIC ACID, CALCIUM ION, ... | | 著者 | Cleasby, A, Tisi, D. | | 登録日 | 2022-05-26 | | 公開日 | 2022-09-21 | | 最終更新日 | 2022-11-02 | | 実験手法 | X-RAY DIFFRACTION (1.56 Å) | | 主引用文献 | Fragment-Based Discovery of a Novel, Brain Penetrant, Orally Active HDAC2 Inhibitor.
Acs Med.Chem.Lett., 13, 2022
|
|
7ZZW
 | | Ligand binding to HDAC2 | | 分子名称: | 1,2-ETHANEDIOL, 2-(cyclohexylazaniumyl)ethanesulfonate, CALCIUM ION, ... | | 著者 | Cleasby, A, Tisi, D. | | 登録日 | 2022-05-26 | | 公開日 | 2022-09-21 | | 最終更新日 | 2022-11-02 | | 実験手法 | X-RAY DIFFRACTION (1.73 Å) | | 主引用文献 | Fragment-Based Discovery of a Novel, Brain Penetrant, Orally Active HDAC2 Inhibitor.
Acs Med.Chem.Lett., 13, 2022
|
|
7ZZU
 | | Inhibitory Ligand binding to HDAC2 | | 分子名称: | 1,2-ETHANEDIOL, 2-[4-[(2~{R},4~{S})-4-phenylpyrrolidin-2-yl]carbonylpiperazin-1-yl]pyridine-3-carbonitrile, 2-[N-CYCLOHEXYLAMINO]ETHANE SULFONIC ACID, ... | | 著者 | Cleasby, A, Tisi, D. | | 登録日 | 2022-05-26 | | 公開日 | 2022-09-21 | | 最終更新日 | 2022-11-02 | | 実験手法 | X-RAY DIFFRACTION (1.85 Å) | | 主引用文献 | Fragment-Based Discovery of a Novel, Brain Penetrant, Orally Active HDAC2 Inhibitor.
Acs Med.Chem.Lett., 13, 2022
|
|
7D1C
 | |
7D19
 | |
5EBX
 | |
7C6B
 | | Crystal structure of Ago2 MID domain in complex with 6-(3-(2-carboxyethyl)phenyl)purine riboside monophosphate | | 分子名称: | 3-[3-[9-[(2R,3R,4S,5R)-3,4-bis(oxidanyl)-5-(phosphonooxymethyl)oxolan-2-yl]purin-6-yl]phenyl]propanoic acid, PHOSPHATE ION, Protein argonaute-2 | | 著者 | Suzuki, M, Takahashi, Y, Saito, J, Miyagi, H, Shinohara, F. | | 登録日 | 2020-05-21 | | 公開日 | 2020-11-25 | | 最終更新日 | 2023-11-29 | | 実験手法 | X-RAY DIFFRACTION (1.7 Å) | | 主引用文献 | siRNA potency enhancement via chemical modifications of nucleotide bases at the 5'-end of the siRNA guide strand.
Rna, 27, 2021
|
|
7D7U
 | | Crystal structure of Ago2 MID domain in complex with 8-Br-adenosin-5'-monophosphate | | 分子名称: | 8-BROMO-ADENOSINE-5'-MONOPHOSPHATE, Protein argonaute-2 | | 著者 | Suzuki, M, Takahashi, Y, Saito, J, Miyagi, H, Shinohara, F. | | 登録日 | 2020-10-06 | | 公開日 | 2020-11-25 | | 最終更新日 | 2023-11-29 | | 実験手法 | X-RAY DIFFRACTION (2 Å) | | 主引用文献 | siRNA potency enhancement via chemical modifications of nucleotide bases at the 5'-end of the siRNA guide strand.
Rna, 27, 2021
|
|
7XLL
 | |
7WVA
 | |
7XAR
 | | Crystal structure of 3C-like protease from SARS-CoV-2 in complex with covalent inhibitor | | 分子名称: | 3C-like proteinase, 4-fluoranyl-~{N}-[(2~{S})-1-[2-(2-fluoranylethanoyl)-2-[[(3~{S})-2-oxidanylidenepyrrolidin-3-yl]methyl]hydrazinyl]-4-methyl-1-oxidanylidene-pentan-2-yl]-1~{H}-indole-2-carboxamide, CHLORIDE ION, ... | | 著者 | Caaveiro, J.M.M, Ochi, J, Takahashi, D, Ueda, T, Ojida, A. | | 登録日 | 2022-03-18 | | 公開日 | 2022-11-09 | | 最終更新日 | 2023-11-29 | | 実験手法 | X-RAY DIFFRACTION (1.6 Å) | | 主引用文献 | Discovery of Chlorofluoroacetamide-Based Covalent Inhibitors for Severe Acute Respiratory Syndrome Coronavirus 2 3CL Protease.
J.Med.Chem., 65, 2022
|
|
6EBX
 | |
7E5O
 | | Crystal structure of SARS-CoV-2 RBD in complex with antibody NT-193 | | 分子名称: | 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose, NT-193 Heavy chain, NT-193 Light chain, ... | | 著者 | Kita, S, Onodera, T, Adachi, Y, Moriayma, S, Nomura, T, Tadokoro, T, Anraku, Y, Yumoto, K, Tian, C, Fukuhara, H, Suzuki, T, Tonouchi, K, Sasaki, J, Sun, L, Hashiguchi, T, Takahashi, Y, Maenaka, K. | | 登録日 | 2021-02-19 | | 公開日 | 2021-09-08 | | 最終更新日 | 2023-11-29 | | 実験手法 | X-RAY DIFFRACTION (2.8 Å) | | 主引用文献 | A SARS-CoV-2 antibody broadly neutralizes SARS-related coronaviruses and variants by coordinated recognition of a virus-vulnerable site.
Immunity, 54, 2021
|
|
1KRM
 | |
